title: Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration.
abstract: BACKGROUND
  Control of glycaemic levels as well as cardiovascular risk factors (CVRF) is essential to prevent the onset of complications associated with type 2 diabetes mellitus (T2DM).
  
  
  OBJECTIVE
  To describe the degree of glycaemic control and CVRF in relation to diabetes duration.
  
  
  METHODS
  Multicentre cross-sectional study in T2DM patients seen in primary care centres during 2007.
  
  
  METHODS
  Demographical and clinical characteristics, antidiabetic treatments and development of disease complications. Diabetes duration classification: 0-5, 6-10, 11-20 and >20 years. Logistic regression models were used in the analysis.
  
  
  RESULTS
  A total of 3130 patients; 51.5% males; mean age: 68±11.7 years; mean diabetes duration:7.0 (±5.6) years, median: 5 (interquartile range:3-9) years; mean HbA1c: 6.84 (±1.5), were analyzed. There has been a progressive decline in HbA1c levels (HbA1c > 7% in 25.8% of patients during the first 5 years and 51.8% after 20 years). Blood pressure values remained relatively stable throughout disease duration. The mean value of low density lipoprotein (LDL) experienced a slight decline with the progression of the disease, but due to the significant increase of cardiovascular disease (CVD) after 20 years of duration, less patients reached the recommended target (LDL < 100mg/dl) in secondary prevention. Logistic regression model controlling for age, sex and CVD showed that diabetes duration was related to glycaemic control (odds ratio: 1.066, 95% confidence interval: 1.050-1.082 per year) but not to blood pressure or LDL control.
  
  
  CONCLUSIONS
  The degree of glycaemic control and the risk factors in relation to the duration of T2DM followed different patterns. Diabetes duration was associated with a poorer glycaemic control but in general had a limited role in blood pressure control or lipid profile.
authors.affiliation: Primary Care Center Raval Sud, Barcelona, Spain; Barcelona Ciutat Research Support Unit - IDIAP Jordi Gol, Barcelona, Spain; josep.franch@gmail.com.
authors.forename: Josep
authors.initials: J
authors.lastname: Franch-Nadal
authors.affiliation: PCC Badía del Vallés, Barcelona, Spain;
authors.forename: Pilar
authors.initials: P
authors.lastname: Roura-Olmeda
authors.affiliation: Primary Care Center Raval Sud, Barcelona, Spain;
authors.forename: Belén
authors.initials: B
authors.lastname: Benito-Badorrey
authors.affiliation: PCC Anglés, Girona, Spain; Research Unit, Healthcare Institute, Girona, Spain;
authors.forename: Antonio
authors.initials: A
authors.lastname: Rodriguez-Poncelas
authors.affiliation: PCC Anglés, Girona, Spain; Research Unit, Healthcare Institute, Girona, Spain; Translab. Departament of Medical Sciences, University of Girona, Girona, Spain and.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Coll-de-Tuero
authors.affiliation: Barcelona Ciutat Research Support Unit - IDIAP Jordi Gol, Barcelona, Spain; PCC La Mina, Sant Adrià de Besòs, Barcelona, Spain.
authors.forename: Manel
authors.initials: M
authors.lastname: Mata-Cases
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology; D008078:Cholesterol, LDL / Q000097:blood*; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications*; D006973:Hypertension / Q000097:blood / Q000150:complications*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents
keywords: Cardiovascular risk factors; T2DM.; control; disease duration